Karolinska Development
is supported by the European
Union through the “Technology
Transfer Pilot Project”
Karolinska Development
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.
An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 36 projects, of which 14 are in clinical development.
Karolinska Development's flexible exit strategy enables projects to be exited at whichever stage of development offers the best return on investment, usually after Phase II clinical trials have shown pharmaceutical efficacy on patients – this being an important value enhancing step.
Since its inception in 2003, Karolinska Development's portfolio has evolved from projects mainly in lead optimization phase into a balanced portfolio of pharmaceutical development projects in all phases from discovery to Phase II. During these years, the portfolio has grown from 15 projects to 36. At the same time, a few technology projects have reached the market. The portfolio is particularly strong in the areas of cancer, dermatology, inflammation, cardiovascular disease, women's health and diseases that affect the central nervous system.
Among the pharmaceutical development projects, 25 have reached lead optimization phase or beyond. 14 projects are in clinical phase. In addition to the pharmaceutical development projects, the portfolio also includes eight technology platforms or medical devices. The projects are run within 27 partly-owned portfolio companies, of which 23 are active investments in which Karolinska Development takes an active ownership role. The other four are considered to be passive financial investments.
Portfolio development overview
The portfolio has increased from a total of 15 projects in 2003 to 36 projects as of today.
Significant progress has also been made in advancing projects into clinical phase, from four
projects in 2007 to todays 14.
